Home › Upcoming votes › GALECTIN THERAPEUTICS INC
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in GALECTIN THERAPEUTICS INC’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | ELECTION OF DIRECTORS Director election |
Board | For | 11 nominees; support 97% to 99% |
| 2 | TO ADOPT AND APPROVE AN AMENDMENT TO OUR RESTATED ARTICLES OF INCORPORATION INCREASING THE NUMBER OF AUTHORIZED COMMON STOCK FROM 150,000,000 TO 250,000,000 | Board | For | — |
| 3 | TO APPROVE AN AMENDMENT TO OUR 2019 OMNIBUS EQUITY INCENTIVE PLAN | Board | For | — |
| 4 | RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS Auditor |
Board | For | — |
From GALECTIN THERAPEUTICS INC’s Form 8-K, filed December 8, 2025, for the meeting held December 3, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Gilbert F. Amelio, Ph.D. | 97% | Elected |
| Elect Director: Benjamin S. Carson, Sr., M.D. | 99% | Elected |
| Elect Director: Kary Eldred | 99% | Elected |
| Elect Director: Kevin D. Freeman | 99% | Elected |
| Elect Director: Joel Lewis | 98% | Elected |
| Elect Director: Gilbert S. Omenn, M.D., Ph.D. | 98% | Elected |
| Elect Director: Marc Rubin, M.D. | 99% | Elected |
| Elect Director: Elissa J. Schwartz, Ph.D. | 99% | Elected |
| Elect Director: Harold H. Shlevin, Ph.D. | 98% | Elected |
| Elect Director: Richard E. Uihlein, Chairman | 99% | Elected |
| Elect Director: Richard A. Zordani | 99% | Elected |
| Vote on a non-binding advisory resolution to approve the compensation paid to Galectin's named executive officers, as disclosed in the proxy | 98% | — |
| - 2 - Recommendation, by non-binding vote, the frequency with which Galectin will conduct stockholder advisory votes on executive compensati | 99.6% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.